Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of REGENERON PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000872589.
Disclosed value leader
VANGUARD CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
10 Aug 2026
- Public ticker
- REGN on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
10 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000872589
- Issuer location
- Tarrytown, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of REGENERON PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
VANGUARD CAPITAL MANAGEME...
Comparable rows
50/50
Latest evidence
10 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.4%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 7.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
7.4%
JPMORGAN CHASE & CO
4.4%
FMR LLC
3.2%
Huda Y. Zoghbi
0%
BlackRock, Inc.
8.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.4%
|
$5,919,048,238
7,660,810 shares
|
$0 | 31 Mar 2026 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
4.4%
|
$2,729,989,170
4,742,611 shares
|
-$462,704,633 | 30 May 2025 |
| FMR LLC |
13D/G
13F
Company
|
3.2%
|
$1,880,548,739
3,359,563 shares
|
-$2,703,197,470 | 30 Jun 2025 |
| Huda Y. Zoghbi |
3/4/5
Director
|
0%
|
$1,061,888
1,703 shares
|
-$1,279,812 | 10 Aug 2026 |
| BlackRock, Inc. |
13F
Company
|
8.8%
|
$5,682,635,642
9,113,506 shares
|
— | 30 Jun 2026 |
| DODGE & COX |
13F
Company
|
4.7%
|
$3,037,348,765
4,871,137 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
4.7%
|
$3,014,621,356
4,834,688 shares
|
— | 30 Jun 2026 |
| Invesco Ltd. |
13F
Company
|
3.8%
|
$2,457,161,872
3,940,665 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$12,265,523.
Buys
$0
Insiders: 0
Sells
$12,265,523
Insiders: 7
Net
-$12,265,523
Shares: -16,611
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 16,611
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,346 | $0 | $2,792,488 | -$2,792,488 |
| 3-6 | 0 | 200 | $0 | $148,251 | -$148,251 |
| 6-9 | 0 | 5,374 | $0 | $4,221,272 | -$4,221,272 |
| 9-12 | 0 | 7,691 | $0 | $5,103,512 | -$5,103,512 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to REGENERON PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
George D. Yancopoulos
Net 12M change
-$12,265,522
Latest report
02 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| George D. Yancopoulos | Bd. Co-Chair, President & CSO, Director | $804,491,660 | Mixed | 31 Dec 2025 | ||
| Leonard S. Schleifer | Bd. Co-Chair, President & CEO, Director | $493,538,603 | Mixed | 31 Dec 2025 | ||
| VAGELOS P ROY | Director | $444,337,350 | Mixed | 03 Apr 2023 | ||
| Neil E. Stahl | EVP Research and Development | $43,324,609 | Mixed | 16 Dec 2024 | ||
| Andrew J. Murphy | EVP Research | $36,595,908 | Mixed | 09 Dec 2025 | ||
| Joseph J. Larosa | EVP General Counsel and Secret | $28,430,305 | Median | 19 Aug 2026 | ||
| George L. Sing | Director | $25,592,887 | Mixed | 02 Jan 2026 | ||
| Daniel P. van Plew | EVP & General Mgr, Industrial | $24,589,665 | Mixed | 09 Dec 2025 | ||
| Robert E. Landry | EVP Finance CFO | $22,918,280 | Mixed | 02 Feb 2024 | ||
| Christopher R. Fenimore | EVP Finance CFO | $14,656,305 | Median | 18 Aug 2026 | ||
| Arthur F. Ryan | Director | $11,249,545 | -$434,683 | -3.7% | Filing P/S | 02 Jul 2026 |
| Marion McCourt | EVP Commercial | $10,427,807 | -$2,002,458 | -16% | Mixed | 02 Sep 2026 |
| Michael S. Brown | Director | $9,930,105 | Mixed | 02 Jan 2026 | ||
| Joseph L. Goldstein | Director | $5,173,843 | Mixed | 02 Jan 2026 | ||
| Christine A. Poon | Director | $4,028,389 | -$4,252,745 | -51% | Mixed | 02 Jan 2026 |
| Jason Pitofsky | SVP Controller | $3,516,873 | -$1,865,824 | -35% | Mixed | 09 Feb 2026 |
| Marc Tessier-Lavigne | Director | $2,315,367 | Mixed | 03 Jan 2023 | ||
| Bonnie L. Bassler | Director | $1,362,400 | -$1,770,000 | -57% | Filing P/S | 07 Jan 2026 |
| N. Anthony Coles | Director | $1,322,985 | Mixed | 02 Jan 2026 | ||
| Huda Y. Zoghbi | Director | $1,061,888 | -$1,279,812 | -55% | Median | 10 Aug 2026 |
Recent insider transactions for REGENERON PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Marion McCourt | REGN | Common Stock | Sale | -8.61% | $969,708 | $857.39 | -1,131 | 12,003 | 03 Sep 2026 | Direct |
| Marion McCourt | REGN | Common Stock | Sale | -8.47% | $1,032,750 | $850.00 | -1,215 | 13,134 | 02 Sep 2026 | Direct |
| Kathryn Guarini | REGN | Common Stock | Sale | -39.9% | $340,000 | $850.00 | -400 | 603 | 02 Sep 2026 | Direct |
| Kathryn Guarini | REGN | Common Stock | Options Exercise | 66.3% | 400 | 1,003 | 02 Sep 2026 | Direct | ||
| Kathryn Guarini | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -25.7% | -400 | 1,158 | 02 Sep 2026 | Direct | ||
| Joseph J. Larosa | REGN | Common Stock | Tax liability | -19.9% | -9,019 | 36,373 | 19 Aug 2026 | Direct | ||
| Joseph J. Larosa | REGN | Common Stock | Options Exercise | 37.1% | 12,282 | 45,392 | 19 Aug 2026 | Direct | ||
| Joseph J. Larosa | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -50% | -12,282 | 12,283 | 19 Aug 2026 | Direct | ||
| Christopher R. Fenimore | REGN | Common Stock | Tax liability | -18.7% | -4,599 | 19,984 | 18 Aug 2026 | Direct | ||
| Christopher R. Fenimore | REGN | Common Stock | Options Exercise | 34.3% | 6,283 | 24,583 | 18 Aug 2026 | Direct | ||
| Christopher R. Fenimore | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -51.2% | -6,283 | 6,000 | 18 Aug 2026 | Direct | ||
| Kathryn Guarini | REGN | Common Stock | Sale | -39.9% | $320,000 | $800.00 | -400 | 603 | 10 Aug 2026 | Direct |
| Kathryn Guarini | REGN | Common Stock | Options Exercise | 66.3% | 400 | 1,003 | 10 Aug 2026 | Direct | ||
| Kathryn Guarini | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -20.4% | -400 | 1,558 | 10 Aug 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Common Stock | Sale | -32% | -800 | 1,703 | 10 Aug 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Common Stock | Options Exercise | 47% | 800 | 2,503 | 10 Aug 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -800 | 0 | 10 Aug 2026 | Direct | ||
| Arthur F. Ryan | REGN | Common Stock | Sale | -1.14% | $130,030 | $650.15 | -200 | 17,303 | 02 Jul 2026 | Direct |
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.57% | $70,524 | $705.24 | -100 | 17,503 | 01 May 2026 | Direct |
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $77,727 | $777.27 | -100 | 17,603 | 01 Apr 2026 | Direct |
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $78,550 | $785.50 | -100 | 17,703 | 02 Mar 2026 | Direct |
| Huda Y. Zoghbi | REGN | Common Stock | Sale | -49% | $1,279,812 | $781.33 | -1,638 | 1,703 | 19 Feb 2026 | Direct |
| Huda Y. Zoghbi | REGN | Common Stock | Options Exercise | 96.2% | 1,638 | 3,341 | 19 Feb 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -67.2% | -1,638 | 800 | 19 Feb 2026 | Direct | ||
| Jason Pitofsky | REGN | Common Stock | Sale | -32.3% | $1,585,058 | $778.52 | -2,036 | 4,272 | 09 Feb 2026 | Direct |
| Jason Pitofsky | REGN | Common Stock | Options Exercise | 18.8% | 1,000 | 6,308 | 09 Feb 2026 | Direct | ||
| Jason Pitofsky | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -52.5% | -1,000 | 905 | 09 Feb 2026 | Direct | ||
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $77,853 | $778.53 | -100 | 17,803 | 09 Feb 2026 | Direct |
| Bonnie L. Bassler | REGN | Common Stock | Sale | -46.8% | $1,200,000 | $800.00 | -1,500 | 1,703 | 07 Jan 2026 | Direct |
| Bonnie L. Bassler | REGN | Common Stock | Options Exercise | 88.1% | 1,500 | 3,203 | 07 Jan 2026 | Direct | ||
| Bonnie L. Bassler | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -34.4% | -1,500 | 2,861 | 07 Jan 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Craig B. Thompson | REGN | Common Stock | Award | 25% | 155 | 775 | 02 Jan 2026 | Direct | ||
| Craig B. Thompson | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| George L. Sing | REGN | Common Stock | Award | 0.5% | 155 | 31,007 | 02 Jan 2026 | Direct | ||
| George L. Sing | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Kathryn Guarini | REGN | Common Stock | Award | 34.6% | 155 | 603 | 02 Jan 2026 | Direct | ||
| Kathryn Guarini | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| David P. Schenkein | REGN | Common Stock | Award | 34.6% | 155 | 603 | 02 Jan 2026 | Direct | ||
| David P. Schenkein | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Joseph L. Goldstein | REGN | Common Stock | Award | 2.37% | 155 | 6,703 | 02 Jan 2026 | Direct | ||
| Joseph L. Goldstein | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Arthur F. Ryan | REGN | Common Stock | Award | 0.87% | 155 | 17,903 | 02 Jan 2026 | Direct | ||
| Arthur F. Ryan | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| N. Anthony Coles | REGN | Common Stock | Award | 9.94% | 155 | 1,714 | 02 Jan 2026 | Direct | ||
| N. Anthony Coles | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Michael S. Brown | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct | ||
| Michael S. Brown | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Bonnie L. Bassler | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.